Data from first DMT-assisted clinical trial revealed
No sign of significant negative effects on anxiety and wellbeing following pioneering Small Pharma trial
Read Moreby John Pinching | Feb 24, 2022 | News | 0
No sign of significant negative effects on anxiety and wellbeing following pioneering Small Pharma trial
Read Moreby Selina McKee | Sep 3, 2020 | News | 0
NICE has concerns with the evidence submitted but Janssen insists the nasal spray is a cost-effective use of NHS resources
Read Moreby Selina McKee | Jul 22, 2020 | News | 0
US regulators have, however, accepted the drug for review to treat hallucinations and delusions associated with dementia-related psychosis
Read Moreby Selina McKee | Mar 7, 2019 | News | 0
Allergan’s rapastinel has failed to hit its primary endpoints in three late-stage studies assessing its potential as an adjunctive treatment for depression.
Read Moreby Selina McKee | Nov 2, 2018 | News | 0
Alkermes’ ALKS 5461 has been hit with a potential setback in the US after regulatory advisors failed to back its approval for major depressive disorder (MDD).
Read Moreby Selina McKee | Oct 11, 2018 | News | 0
Janssen has submitted a marketing application to the European Medicines Agency (EMA) seeking approval of investigational nasal spray esketamine for the treatment of major depressive disorder.
Read Moreby Selina McKee | Apr 6, 2017 | News | 0
Allergan has reported mixed top-line data from a mid-stage trial testing Botox as a treatment for major depressive disorder (MDD), but says the results are “encouraging” and warrant a move into Phase III development.
Read Moreby Selina McKee | Oct 21, 2016 | News | 0
Shares in Ireland-headquartered Alkermes shot up nearly 50 percent after its experimental depression drug hit targets in a pivotal late-stage trial.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
